Article
Oncology
S. Rothschild, R. Nachbur, N. Herzog, J. R. Passweg, M. Pless
Summary: The study found that nearly 40% of NSCLC patients are primary refractory to first-line palliative chemotherapy, with a poor prognosis. Active second-line therapy can significantly improve outcomes, and thus should be offered to patients with primary refractory NSCLC.
Review
Oncology
Martin Reck, Jordi Remon, Matthew D. Hellmann
Summary: The past decade has seen significant progress in the treatment of metastatic non-small-cell lung cancer, with the development of specific antibodies leading to improved survival for many patients. Currently, nearly all mNSCLC patients receive PD-1 or PD-L1 therapy in the first-line setting, except those with targetable oncogenes.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Qian-Yu Yang, Lin Zhu, Hong-Xia Liu, Qing-Shan Zheng, Lu-Jin Li
Summary: The objective of this study was to quantify the efficacies and safety profiles of the three first-line non-platinum chemotherapy regimens recommended in the National Comprehensive Cancer Network guidelines. The analysis found no significant difference in overall survival or toxicity among the three regimens. Age and performance status scores were significant predictors of overall survival and their heterogeneity across different studies should be considered in cross-study comparisons and sample size estimations when designing clinical trials.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Oncology
Jon Zugazagoitia, Luis Paz-Ares
Summary: Extensive-stage small-cell lung cancer is a challenging disease to treat, and despite improvements in first-line therapy, resistance remains a significant issue. Recent progress in understanding the molecular biology of SCLC holds potential for molecularly informed therapeutic strategies for patients with SCLC.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Melina E. Marmarelis, Yu-Xiao Yang, Wei-Ting Hwang, Ronac Mamtani, Aditi Singh, Christine Ciunci, Charu Aggarwal, Roger B. Cohen, Corey J. Langer
Summary: This study analyzed NSCLC patients who underwent immunotherapy and found that the platinum-free-interval did not predict better outcomes after platinum re-exposure.
CLINICAL LUNG CANCER
(2022)
Article
Oncology
Motoki Sekikawa, Haruyasu Murakami, Meiko Morita, Kosei Doshita, Keita Miura, Hiroaki Kodama, Noboru Morikawa, Yuko Iida, Nobuaki Mamesaya, Haruki Kobayashi, Ryo Ko, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Hirofumi Chiba, Toshiaki Takahashi
Summary: In this study, the safety and efficacy of Amrubicin (AMR) with or without primary prophylactic pegfilgrastim (P-PEG) as second-line chemotherapy for small cell lung cancer (SCLC) were evaluated. The results showed that AMR with P-PEG reduced the incidence of febrile neutropenia, maintained the dose intensity of AMR, and was associated with favorable tumor responses and survival outcomes.
Article
Oncology
Luis Paz-Ares, David R. Spigel, Yuanbin Chen, Maria Jove, Oscar Juan-Vidal, Patricia Rich, Theresa Hayes, Vanesa Gutierrez Calderon, Reyes Bernabe Caro, Alejandro Navarro, Afshin Dowlati, Bin Zhang, Yan Moore, Xiaopan Yao, Jaba Kokhreidze, Santiago Ponce, Paul A. Bunn
Summary: This study evaluated the safety and efficacy of liposomal irinotecan monotherapy in patients with small cell lung cancer. Among the 25 patients included in the study, 10 experienced severe adverse events, with diarrhea and neutropenia being the most common side effects. The objective response rate was 44%, and the average survival and time to disease progression were 8.08 and 3.98 months, respectively.
Review
Oncology
Jeffrey Ahn, Misako Nagasaka
Summary: This paper reviews the application of PD-1 and PD-L1 inhibitors in first line treatment for metastatic non-small cell lung cancer (NSCLC), particularly for tumors without EGFR mutations, ALK and ROS gene fusions. These inhibitors have become a cornerstone as monotherapy or in combination with chemotherapy. The paper also discusses the use of cemiplimab-rwlc, the third PD-1/L1 inhibitor in this treatment setting, and provides a perspective on its patient population and primary efficacy results in the context of first line therapies for NSCLC.
CANCER MANAGEMENT AND RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Jessica D. Silva, Joana Marques, Ines P. Santos, Ana L. M. Batista de Carvalho, Clara B. Martins, Raquel C. Laginha, Luis A. E. Batista de Carvalho, Maria Paula M. Marques
Summary: A dinuclear Pt(II) complex with putrescine as bridging polyamine ligand was synthesized and evaluated for its potential anticancer activity against a human non-small cell lung cancer line, as well as non-cancer cells. In vitro cytotoxicity assays, microFTIR, and microRaman spectroscopies were used to assess the effect of the complex. The complex showed a major impact on cellular proteins and lipids in cancer cells, while exhibiting lower toxicity towards non-malignant cells.
Review
Pathology
Firoozeh Abolhasani Zadeh, Ahmed Raji, Sana Abdul-Jabbar Ali, Walid Kamal Abdelbasset, Natalia Alekhina, A. Heri Iswanto, Ermias Mergia Terefe, Abduladheem Turki Jalil
Summary: This study provides an overview of the complexity of autophagy in response to chemoradiotherapy in lung cancer. It highlights the dual role of autophagy in both sensitizing cancer cells to therapy and promoting their survival.
PATHOLOGY RESEARCH AND PRACTICE
(2022)
Article
Medicine, General & Internal
Heather Wakelee, Moishe Liberman, Terufumi Kato, Masahiro Tsuboi, Se-Hoon Lee, Shugeng Gao, Ke-Neng Chen, Christophe Dooms, Margarita Majem, Ekkehard Eigendorff, Gaston L. Martinengo, Olivier Bylicki, Delvys Rodriguez-Abreu, Jamie E. E. Chaft, Silvia Novello, Jing Yang, Steven M. M. Keller, Ayman Samkari, Jonathan D. D. Spicer
Summary: Among patients with resectable early-stage NSCLC, perioperative pembrolizumab improved event-free survival, major pathological response, and pathological complete response. The addition of pembrolizumab to neoadjuvant chemotherapy followed by surgery showed significant benefits compared to neoadjuvant chemotherapy alone followed by surgery.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Immunology
Dongna Chen, Lin Li, Mingzhao Wang, Xingsheng Hu, Jun Jiang, Weihua Li, Lin Yang, Meng Fan, Yuankai Shi, Fang Lv, Yutao Liu
Summary: This study retrospectively collected clinical data from patients with metastatic NSCLC who received immunotherapy plus single-agent chemotherapy as a second- or later-line treatment. The results showed that this treatment regimen is safe, effective, and tolerable for metastatic NSCLC, and EV markers can be used as predictive markers of treatment efficacy.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Oncology
Kohei Horiuchi, Takashi Sato, Toshiki Kuno, Hisato Takagi, Fred R. Hirsch, Charles A. Powell, Koichi Fukunaga
Summary: Platinum-doublet chemotherapy shows higher objective response rate and disease control rate as a second-line treatment option for patients with relapsed small-cell lung cancer compared to non-platinum regimens, making it a reasonable choice.
Article
Oncology
Eriko Miyawaki, Hirotsugu Kenmotsu, Yasushi Shintani, Ikuo Sekine, Takehito Shukuya, Koichi Takayama, Akira Inoue, Isamu Okamoto, Katsuyuki Kiura, Kazuhisa Takahashi, Nobuyuki Yamamoto, Tomoya Kawaguchi, Etsuo Miyaoka, Ichiro Yoshino, Hiroshi Date
Summary: This study evaluated the efficacy of platinum-doublet chemotherapy as a second-line treatment for patients with unresectable stage III NSCLC following platinum-based chemoradiotherapy. The results showed that platinum-doublet chemotherapy significantly improved overall survival and may be a promising treatment for these patients.
Review
Oncology
Giannis Mountzios, Jordi Remon, Lizza E. L. Hendriks, Rosario Garcia-Campelo, Christian Rolfo, Paul Van Schil, Patrick M. Forde, Benjamin Besse, Vivek Subbiah, Martin Reck, Jean-Charles Soria, Solange Peters
Summary: Several trials are being conducted to test immune-checkpoint inhibitors (ICIs) in patients with resectable non-small-cell lung cancer as adjuvant, neoadjuvant or perioperative approaches. However, the efficacy of ICIs with curative intent in early stage non-small-cell lung cancer remains unclear. This review discusses the current trial landscape, challenges, and opportunities.
NATURE REVIEWS CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Takaaki Hasegawa, Toshiyuki Sawa, Yohei Futamura, Akane Horiba, Takashi Ishiguro, Tsutomu Marui, Tsutomu Yoshida
Article
Oncology
Tetsuya Abe, Koji Takeda, Yuichiro Ohe, Shinzoh Kudoh, Yukito Ichinose, Hiroaki Okamoto, Nobuyuki Yamamoto, Hiroshige Yoshioka, Koichi Minato, Toshiyuki Sawa, Yasuo Iwamoto, Hideo Saka, Junki Mizusawa, Taro Shibata, Shinichiro Nakamura, Masahiko Ando, Akira Yokoyama, Kazuhiko Nakagawa, Nagahiro Saijo, Tomohide Tamura
JOURNAL OF CLINICAL ONCOLOGY
(2015)
Article
Biology
Takaaki Hasegawa, Yohei Futamura, Akane Horiba, Tsutomu Yoshida, Toshitaka Suzuki, Tatsuo Kato, Daizo Kaito, Yasuhi Ohno, Takayoshi Iida, Shinya Hayashi, Toshiyuki Sawa
JOURNAL OF RADIATION RESEARCH
(2016)
Article
Oncology
Masayuki Takeda, Takeharu Yamanaka, Takashi Seto, Hidetoshi Hayashi, Koichi Azuma, Morihito Okada, Shunichi Sugawara, Haruko Daga, Tomonori Hirashima, Kimio Yonesaka, Yoshiko Urata, Haruyasu Murakami, Haruhiro Saito, Akihito Kubo, Toshiyuki Sawa, Eiji Miyahara, Naoyuki Nogami, Kazuhiko Nakagawa, Yoichi Nakanishi, Isamu Okamoto
Article
Oncology
H. Yoshioka, I. Okamoto, S. Morita, M. Ando, K. Takeda, T. Seto, N. Yamamoto, H. Saka, S. Atagi, T. Hirashima, S. Kudoh, M. Satouchi, N. Ikeda, Y. Iwamoto, T. Sawa, Y. Nakanishi, K. Nakagawa
ANNALS OF ONCOLOGY
(2013)
Article
Oncology
Haruyasu Murakami, Takeharu Yamanaka, Takashi Seto, Kenji Sugio, Isamu Okamoto, Toshiyuki Sawa, Tomonori Hirashima, Koji Takeda, Shinji Atagi, Masahiro Fukuoka, Yoichi Nakanishi, Kazuhiko Nakagawa, Nobuyuki Yamamoto
Article
Oncology
Koji Takeda, Shunichi Negoro, Masahiro Tanaka, Haruhiko Fukuda, Kazuhiko Nakagawa, Masaaki Kawahara, Hiroshi Semba, Shinzoh Kudoh, Toshiyuki Sawa, Nagahiro Saijo, Masahiro Fukuoka
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2011)
Article
Oncology
Hiroko Tsukada, Akira Yokoyama, Koichi Goto, Tetsu Shinkai, Masao Harada, Masahiko Ando, Taro Shibata, Yuichiro Ohe, Tomohide Tamura, Nagahiro Saijo
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
(2015)
Article
Oncology
Koji Takeda, Toyoaki Hida, Tosiya Sato, Masahiko Ando, Takashi Seto, Miyako Satouchi, Yukito Ichinose, Nobuyuki Katakami, Nobuyuki Yamamoto, Shinzoh Kudoh, Jiichiro Sasaki, Kaoru Matsui, Koichi Takayama, Tatsuhiko Kashii, Yasuo Iwamoto, Toshiyuki Sawa, Isamu Okamoto, Takayasu Kurata, Kazuhiko Nakagawa, Masahiro Fukuoka
JOURNAL OF CLINICAL ONCOLOGY
(2010)
Article
Oncology
Isamu Okamoto, Hiroshige Yoshioka, Satoshi Morita, Masahiko Ando, Koji Takeda, Takashi Seto, Nobuyuki Yamamoto, Hideo Saka, Kazuhiro Asami, Tomonori Hirashima, Shinzoh Kudoh, Miyako Satouchi, Norihiko Ikeda, Yasuo Iwamoto, Toshiyuki Sawa, Masaki Miyazaki, Kenji Tamura, Takayasu Kurata, Masahiro Fukuoka, Kazuhiko Nakagawa
JOURNAL OF CLINICAL ONCOLOGY
(2010)
Article
Oncology
Yukito Ichinose, Takashi Seto, Tomonari Sasaki, Takeharu Yamanaka, Isamu Okamoto, Koji Takeda, Masahiro Tanaka, Nobuyuki Katakami, Toshiyuki Sawa, Shinzoh Kudoh, Hideo Saka, Yasumasa Nishimura, Kazuhiko Nakagawa, Masahiro Fukuoka
JOURNAL OF THORACIC ONCOLOGY
(2011)
Article
Oncology
Nobuyuki Katakami, Hiroshi Kunikane, Koji Takeda, Koichi Takayama, Toshiyuki Sawa, Hiroshi Saito, Masao Harada, Soichiro Yokota, Kiyoshi Ando, Yuko Saito, Isao Yokota, Yasuo Ohashi, Kenji Eguchi
JOURNAL OF THORACIC ONCOLOGY
(2014)
Article
Oncology
Shinji Atagi, Masaaki Kawahara, Akira Yokoyama, Hiroaki Okamoto, Nobuyuki Yamamoto, Yuichiro Ohe, Toshiyuki Sawa, Satoshi Ishikura, Taro Shibata, Haruhiko Fukuda, Nagahiro Saijo, Tomohide Tamura
Article
Oncology
Takayasu Kurata, Tomonori Hirashima, Yasuo Iwamoto, Tomoya Kawaguchi, Norihiko Ikeda, Masahiro Tsuboi, Toshiyuki Sawa, Takashi Ishiguro, Takuya Aoki, Yoshikazu Kotani, Kazuhiko Nakagawa, Masahiro Fukuoka
Article
Oncology
Isamu Okamoto, Kazuko Sakai, Satoshi Morita, Hiroshige Yoshioka, Hiroyasu Kaneda, Koji Takeda, Tomonori Hirashima, Yoshihito Kogure, Tatsuo Kimura, Toshiaki Takahashi, Shinji Atagi, Takashi Seto, Toshiyuki Sawa, Masashi Yamamoto, Miyako Satouchi, Motoyasu Okuno, Seisuke Nagase, Koichi Takayama, Keisuke Tomii, Tadashi Maeda, Satoshi Oizumi, Shinji Fujii, Yusaku Akashi, Kazumi Nishino, Noriyuki Ebi, Kazuhiko Nakagawa, Yoichi Nakanishi, Kazuto Nishio